Endothelin receptor antagonism in portal hypertension

Expert Opinion on Investigational Drugs

Volumn 18, Issue 2, 2009, Pages 135-142

  Pitts, Kelly R ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Cirrhosis; Endothelin; Endothelin receptor; Portal hypertension

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 2 PYRIDYLCARBAMIC ACID 2 [[5 (2 METHOXYPHENOXY) 6 [[(4 ISOPROPYLPHENYL)SULFONYL]AMINO] 2 MORPHOLINO 4 PYRIMIDINYL]OXY]ETHYL ESTER; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; A 182086; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; TAK 044; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; DATA BASE; DISEASE MODEL; DRUG INDICATION; DRUG POTENTIATION; DRUG SELECTIVITY; EMBASE; HUMAN; IN VIVO STUDY; MEDLINE; NONHUMAN; PORTAL HYPERTENSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; ANIMAL; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; ENDOTHELINS; HUMANS; HYPERTENSION, PORTAL; RECEPTORS, ENDOTHELIN;

EID: 65549165886     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802680186     Document Type: Review

References (47)

1. Treiber G, Csepregi A, Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis 2005;23:6-10 (Pubitemid 40827657)
2. Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000;14:881-894 (Pubitemid 32094263)
3. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407-415
4. Enseleit F, Luscher TF, Ruschitzka F. Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 2008;17:1255-1263
5. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-218 (Pubitemid 46330545)
6. Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis 2006;26:265-272 (Pubitemid 44141934)
7. Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006;36(Suppl 3):54-61 (Pubitemid 44179783)
8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415 • This reference is the first description of endothelin and its vascular activity. (Pubitemid 18090241)
9. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-1373 (Pubitemid 23127334)
10. Seo B, Oemar BS, Siebenmann R, et al. Both ET A and ET B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-1208 (Pubitemid 24076547)
11. Tsukahara H, Ende H, Magazine HI, et al. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 1994;269:21778-21785 (Pubitemid 24274820)
12. de Nucci G, Thomas R, Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797-9800 (Pubitemid 19027212)
13. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-548 (Pubitemid 26043888)
14. Alam I, Bass NM, Bacchetti P, et al. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 2000;95:199-203 (Pubitemid 30041559)
15. Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-739
16. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-1778
17. Uchihara M, Izumi N, Sato C. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992;16:95-99
18. Kuddus RH, Nalesnik MA, Subbotin VM, et al. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 2000;33:725-732 (Pubitemid 30823704)
19. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci USA 1993;90:9266-9270 (Pubitemid 23315764)
20. Rockey DC, Fouassier L, Chung JJ, et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998;27:472-480 (Pubitemid 28081062)
21. Mallat A, Fouassier L, Preaux AM, et al. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest 1995;96:42-49
22. Reinehr RM, Kubitz R, Peters-Regehr T, et al. Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology 1998;28:1566-1577 (Pubitemid 28549127)
23. Reinehr R,Fischer R, Haussinger D. Regulation of endothelin-A receptor sensitivity by cyclic adenosine monophosphate in rat hepatic stellate cells. Hepatology 2002;36:861-873
24. Abraldes JG, Pasarin M, Garcia-Pagan JC. Animal models of portal hypertension. World J Gastroenterol 2006;12:6577-6584 • An excellent review describing several details of portal hypertension models. (Pubitemid 44794932)
25. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-240 (Pubitemid 26249439)
26. Tieche S, De Gottardi A, Kappeler A, et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 2001;34:38-45 (Pubitemid 32102550)
27. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-1030 (Pubitemid 28275982)
28. Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993;104:1485-1491 (Pubitemid 23235424)
29. Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43-50 (Pubitemid 30039446)
30. Thirunavukkarasu C, Yang Y, Subbotin VM, et al. Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. Gut 2004;53:1010-1019 (Pubitemid 38824161)
31. Gandhi CR, Kuddus RH, Uemura T, Rao AS. Endothelin stimulates transforming growth factor-beta1 and collagen synthesis in stellate cells from control but not cirrhotic rat liver. Eur J Pharmacol 2000;406:311-318 (Pubitemid 30782388)
32. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol 2007;37:38-47 (Pubitemid 46999535)
33. De Gottardi A, Shaw S, Sagesser H, Reichen J. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J Hepatol 2000;33:733-737 • An in vivo study suggesting that ETA-selective antagonists may be more beneficial than nonselective antagonists for PHT. (Pubitemid 30823705)
34. Chan CC, Wang SS, Lee FY, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portalhypertensive rats. Hepatology 2001;33:816-820 • An in vivo indicating that ET function in portal-systemic collaterals is ETA receptordependent.
35. Kojima H, Sakurai S, Kuriyama S, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001;34:805-811 • An in vivo study suggesting that nonselective antagonists may be necessary to reduce portal pressure. (Pubitemid 32595178)
36. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528
37. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33 (Pubitemid 26100791)
38. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007;30:1096-1102 (Pubitemid 351194755)
39. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-344 (Pubitemid 47194187)
40. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005;128:164-168
41. Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004;2:1039-1042 •• This reference describes the use of a nonselective antagonist in a single human with PPHT. This is one of the few reports directly showing that chronic ERA treatment reduces the hepatic venous pressure gradient. (Pubitemid 39539755)
42. Tripathi D, Therapondos G, Ferguson JW, et al. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55:1290-1295 •• This reference suggests that acute administration of ET A - or ET B -selective antagonists does not affect the hepatic venous pressure gradient in cirrhotic patients. (Pubitemid 44277360)
43. Cahill PA, Hou MC, Hendrickson R, et al. Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics. Hepatology 1998;28:396-403 (Pubitemid 28363665)
44. Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-659 (Pubitemid 28405411)
45. Gandhi CR, Nemoto EM, Watkins SC, Subbotin VM. An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats. Liver 1998;18:39-48 (Pubitemid 28127756)
46. Kamath PS, Tyce GM, Miller VM, et al. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999;30:401-407 (Pubitemid 29357504)
47. Poo JL, Jimenez W, Maria MR, et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999;116:161-167 (Pubitemid 29013505)